Search Results

Beckman Coulter Diagnostics, a global leader in clinical diagnostics, and MeMed, a leader in the emerging field of advanced host-response technologies, announced expansion of their host immune response diagnostics partnership.

MeMed announces the appointment of Mr. Ori Hadomi as Chairman of the Board of Directors and Mr. Peter Scheu, as President of MeMed US.

Advancing Superior Accuracy in Early Lung Cancer Detection Using Selective Metabolic Pathways and Data Enrichment for Enhanced Diagnostic Capabilities

MeMed is pleased to announce that it has been awarded a contract valued at $727,799 by the Division of Research, Innovation, and Ventures of the U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority.

MeMed, a leader in the emerging field of advanced host response technologies, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for use of the MeMed BV® test on whole blood samples on the point-of-need MeMed Key® analyzer to help healthcare providers distinguish between bacterial and viral infections in 15 minutes.

Beckman Coulter Diagnostics announced today a strategic partnership to jointly develop and commercialize the proven MeMed BV® test, a host immune response diagnostic that is able to distinguish between bacterial and viral infections for use on the Access Family of Immunoassay Analyzers.